0001179110-14-010712.txt : 20140626
0001179110-14-010712.hdr.sgml : 20140626
20140619185345
ACCESSION NUMBER: 0001179110-14-010712
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20140617
FILED AS OF DATE: 20140619
DATE AS OF CHANGE: 20140619
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Karyopharm Therapeutics Inc.
CENTRAL INDEX KEY: 0001503802
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 263931704
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2 MERCER ROAD
CITY: NATICK
STATE: MA
ZIP: 01760
BUSINESS PHONE: 508-975-4820
MAIL ADDRESS:
STREET 1: 2 MERCER ROAD
CITY: NATICK
STATE: MA
ZIP: 01760
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Shacham Sharon
CENTRAL INDEX KEY: 0001588438
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36167
FILM NUMBER: 14931257
MAIL ADDRESS:
STREET 1: C/O KARYOPHARM THERAPEUTICS INC.
STREET 2: 2 MERCER ROAD
CITY: NATICK
STATE: MA
ZIP: 01760
4
1
edgar.xml
FORM 4 -
X0306
4
2014-06-17
0
0001503802
Karyopharm Therapeutics Inc.
KPTI
0001588438
Shacham Sharon
C/O KARYOPHARM THERAPEUTICS INC.
2 MERCER ROAD
NATICK
MA
01760
0
1
0
0
President & CSO
Common Stock
2014-06-17
4
S
0
10000
40.3635
D
908963
D
Common Stock
2014-06-18
4
S
0
10000
43.1523
D
687596
I
By Spouse
This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.50 to $41.00, inclusive. The reporting person undertakes to provide to Karyopharm Therapeutics Inc., any security holder of Karyopharm Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.25 to $43.96, inclusive. The reporting person undertakes to provide to Karyopharm Therapeutics Inc., any security holder of Karyopharm Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) to this Form 4.
/s/ Christopher B. Primiano as Attorney-in-Fact for Sharon Shacham
2014-06-19